Cryptocurrency
Lummis warns CLARITY Act faces 2030 delay risk
US Senator Cynthia Lummis warned lawmakers must pass the CLARITY Act soon or risk delaying comprehensive crypto regulation until at least 2030.
Isaac Francis
Finance JournalistFinance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
Articles by Isaac Francis
Cryptocurrency
US-Iran talks fail as Bitcoin and XRP fall
Talks between the United States and Iran in Islamabad ended without a breakthrough after 21 hours of negotiations, sending Bitcoin lower to around $71,500 and keeping global markets on edge.
St Barbara gold production jumps 49% at Simberi
St Barbara (ASX:SBM) reported a 49% surge in Q3 gold production at Simberi, reaching 13,522 ounces.
Cryptocurrency
SEC opens review of NYSE proposal for Grayscale crypto ETF options
The US Securities and Exchange Commission has formally opened proceedings to review NYSE American’s proposal to list options linked to the Grayscale Coindesk Crypto 5 ETF.
Woodside confirms oil discovery at US Bandit prospect
Woodside Energy (ASX:WDS) has confirmed an oil discovery at the Bandit prospect in the US Gulf of Mexico.
Beetaloo Energy secures $66.3M for gas projects
Beetaloo Energy (ASX:BTL) announced a capital injection, completing a heavily supported $66.3 million institutional placement.
Mont Royal's Ashram Project reveals monstrous scale
Mont Royal’s (ASX:MRZ Ashram Project reveals world-class scale with a massive 204.3Mt resource.
Technology
TerraCom CFO Jen Williams steps down
TerraCom (ASX:TER) announced the resignation of its CFO and company secretary, Jen Williams, effective immediately.
West Cobar Metals targets US federal funding
West Cobar Metals (ASX:WC1) formalised a strategy aimed at securing United States federal funding and downstream partnerships.
MetaVia doses first patient in Part 3 of DA-1726 obesity trial
MetaVia (NASDAQ:MTVA), a clinical-stage biopharmaceutical company focused on metabolic diseases, announced on April 10, 2026, that it has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating DA-1726.